Resources

To achieve sustainability in digital health, we need a shared understanding of market forces and their influence on the digital health sector.Market forces have a role in determining:Which digital health tools get introduced, adopted, and scaled.The underlying costs of digital tools.The long-term opportunities for financing the digital transformation of health systems.Through a series of analyses, PATH Digital Square, Vital Wave, and a consortium of partners whose publications are featured here have identified current challenges to sustainability, outlined cost drivers for digital health software, and developed recommendations, tools, and models that can lead to a more sustainable digital health marketplace.

This slide provides a snapshot of the Group B Streptococcus (GBS) vaccine technology landscape, in the effort to track the development of GBS vaccine candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the GBS Vaccine Clinical Trial Tracker, which provides publicly available information on clinical trials of GBS vaccine candidates intended for disease prevention.To share any updates or corrections to the snapshot, please contact gbssnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of Group B Streptococcus (GBS) candidate vaccines intended for disease prevention.Sources of information for these trials include clinicaltrials.gov, who.int/clinical-trials-registry-platform, clinicaltrialsregister.eu, chictr.org.cn, and anzctr.org.au.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine clinical trials. This spreadsheet pairs with the GBS Vaccine Snapshot, which provides a summary of the GBS vaccine candidates in development worldwide.To share any updates or corrections to the tracker, please contact gbssnapshot@path.org.

To support the development and introduction of more sensitive rapid diagnostic tests (RDTs) for malaria, PATH and the Institut Pasteur de Dakar partnered to evaluate the performance of three novel LDH-based RDTs developed by Rapigen (Republic of Korea). This study evaluated the clinical performance and usability of three of Rapigen’s BIOCREDIT RDTs among a febrile population in Kédougou, Senegal, comparing them to current tests (the standard HRP2-based RDT and microscopy) and against PCR and quantitative antigen reference assays. The following brief summarizes key results from this evaluation.

In 2017, African leaders made a historic commitment to improving access to lifesaving vaccines across the African continent by endorsing the Addis Declaration on Immunization (ADI). This pledge included a targeted goal to expand domestic investments, ensuring that every African benefits from immunization.The Africa Centers for Disease Control and Prevention (CDC) and the African Union Commission conducted a comprehensive review of the ADI to assess the implementation progress of the ten ADI commitments between 2017 and 2023, highlighting areas of slow advancement and disparities in progress among African Union member states. To corroborate this review, findings from a retrospective study, conducted by PATH’s Center for Advocacy and Policy, in nine African countries on immunization financing between 2017 and 2023, provided additional evidence—especially on the fluctuating trends in government financing for immunization.The following immunization advocacy resources include an overview Africa brief, and country-specific briefs that provide key findings and recommendations from the study and highlight common trends, challenges, and opportunities.